NR1D1 and central nervous system cancer: REV-ERBα has been implicated in the progression and development of various cancers.155 Activation of REV-ERBα by SR9009 and SR9011 was found to confer cancer cell-selective cytotoxicity as well asin vivo efficacy against glioma, and autophagy and lipogenesis were identified as cellular hallmarks closely associated with this anti-cancer activity.156 In a recent study investigating lung adenocarcinoma-associated cachexia,157 REV-ERBα functions as a key effector whose exaggerated turnover contributes to gluconeogenesis gene induction and glucose production in mice.